Immunotherapy in Breast Cancer: the New Frontier

Zishuo I. Hu; Heather L. McArthur

doi:10.1007/s12609-018-0274-y

Immunotherapy in Breast Cancer: the New Frontier

Zishuo I. Hu, Heather L. McArthur

Research output: Contribution to journal › Review article › peer-review

20 Scopus citations

Abstract

Purpose of review: This review summarizes current immunotherapies in breast cancer, with an emphasis on immune checkpoint inhibitors and vaccines. Recent findings: Combination immunotherapy with checkpoint inhibitors and cytotoxic therapies have shown promising results. Active clinical trials are ongoing in both early stage and metastatic settings for triple negative, HER2+, and hormone-positive breast cancer patients. Summary: Ongoing challenges remain in defining biomarkers that predict response to immunotherapy, determining the optimal combination immunotherapies, and enhancing the immunogenicity of breast cancer subtypes.

Original language	English (US)
Pages (from-to)	35-40
Number of pages	6
Journal	Current Breast Cancer Reports
Volume	10
Issue number	2
DOIs	https://doi.org/10.1007/s12609-018-0274-y
State	Published - Jun 1 2018
Externally published	Yes

Keywords

Breast cancer
Checkpoint inhibitors
Immunotherapy
Vaccines

ASJC Scopus subject areas

Oncology

Access to Document

10.1007/s12609-018-0274-y

Cite this

@article{73da2a22e34346fda19d564c9e4f54a7,

title = "Immunotherapy in Breast Cancer: the New Frontier",

abstract = "Purpose of review: This review summarizes current immunotherapies in breast cancer, with an emphasis on immune checkpoint inhibitors and vaccines. Recent findings: Combination immunotherapy with checkpoint inhibitors and cytotoxic therapies have shown promising results. Active clinical trials are ongoing in both early stage and metastatic settings for triple negative, HER2+, and hormone-positive breast cancer patients. Summary: Ongoing challenges remain in defining biomarkers that predict response to immunotherapy, determining the optimal combination immunotherapies, and enhancing the immunogenicity of breast cancer subtypes.",

keywords = "Breast cancer, Checkpoint inhibitors, Immunotherapy, Vaccines",

author = "Hu, {Zishuo I.} and McArthur, {Heather L.}",

note = "Publisher Copyright: {\textcopyright} 2018, The Author(s).",

year = "2018",

month = jun,

day = "1",

doi = "10.1007/s12609-018-0274-y",

language = "English (US)",

volume = "10",

pages = "35--40",

journal = "Current Breast Cancer Reports",

issn = "1943-4588",

publisher = "Current Science, Inc.",

number = "2",

}

TY - JOUR

T1 - Immunotherapy in Breast Cancer

T2 - the New Frontier

AU - Hu, Zishuo I.

AU - McArthur, Heather L.

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Purpose of review: This review summarizes current immunotherapies in breast cancer, with an emphasis on immune checkpoint inhibitors and vaccines. Recent findings: Combination immunotherapy with checkpoint inhibitors and cytotoxic therapies have shown promising results. Active clinical trials are ongoing in both early stage and metastatic settings for triple negative, HER2+, and hormone-positive breast cancer patients. Summary: Ongoing challenges remain in defining biomarkers that predict response to immunotherapy, determining the optimal combination immunotherapies, and enhancing the immunogenicity of breast cancer subtypes.

AB - Purpose of review: This review summarizes current immunotherapies in breast cancer, with an emphasis on immune checkpoint inhibitors and vaccines. Recent findings: Combination immunotherapy with checkpoint inhibitors and cytotoxic therapies have shown promising results. Active clinical trials are ongoing in both early stage and metastatic settings for triple negative, HER2+, and hormone-positive breast cancer patients. Summary: Ongoing challenges remain in defining biomarkers that predict response to immunotherapy, determining the optimal combination immunotherapies, and enhancing the immunogenicity of breast cancer subtypes.

KW - Breast cancer

KW - Checkpoint inhibitors

KW - Immunotherapy

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=85045449431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045449431&partnerID=8YFLogxK

U2 - 10.1007/s12609-018-0274-y

DO - 10.1007/s12609-018-0274-y

M3 - Review article

C2 - 29881518

AN - SCOPUS:85045449431

SN - 1943-4588

VL - 10

SP - 35

EP - 40

JO - Current Breast Cancer Reports

JF - Current Breast Cancer Reports

IS - 2

ER -

Immunotherapy in Breast Cancer: the New Frontier

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this